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Prevalence of Malaria Parasite Infections among U.S.-Bound Congolese Refugees with and
without Splenomegaly
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Abstract. All U.S.-bound refugees from sub-Saharan Africa receive presumptive antimalarial treatment before
departing for the United States. Among U.S.-bound Congolese refugees, breakthrough malaria cases and persistent
splenomegaly have been reported. In response, an enhancedmalaria diagnostic programwas instituted. Here, we report
the prevalence of plasmodial infection among 803U.S.-bound Congolese refugees who received enhanced diagnostics.
Infectionsbyeither rapid diagnostic test (RDT) orPCRweredetected in 187 (23%) refugees,with 78 (10%)byRDTonly, 35
(4%) by PCR only, and 74 (9%) by both. Infections identified by PCR included 103 monoinfections (87 Plasmodium
falciparum, eight Plasmodium ovale, seven Plasmodium vivax, and one Plasmodium malariae) and six mixed infections.
Splenomegaly was associated with malaria detectable by RDT (odds ratio: 1.8, 95% CI: 1.0–3.0), but not by PCR.
Splenomegaly was not strongly associated with parasitemia, indicating that active malaria parasitemia is not necessary
for splenomegaly.
During 2013–2019, more than 50,000 Congolese refugees
living in east Africa resettled to the United States. During
2014–2015, 14% of Congolese refugees resettling to the
United States from the Kyangwali Refugee Settlement in the
Kikuube district of Uganda were noted to have splenomeg-
aly.1 A subsequent investigation of splenomegaly in Con-
golese refugees resettled to the United States highlighted
malaria infection as a relatively common condition, although
the definitive etiology of splenomegaly in this population was
not determined.2 These observations led to enhanced diag-
nostics formalaria infection testing for U.S.-boundCongolese
refugees from Kikuube district, Uganda, to better manage
malaria by detecting additional cases and by providing
species-specific treatment. We determined the prevalence of
plasmodial infection among 803 U.S.-bound Congolese ref-
ugees evaluated under this enhanced diagnostics program.
As part of the U.S. Refugee Resettlement Program, all U.S.-
bound refugees originating in sub-Saharan Africa receive
presumptive predeparture treatment with artemether/
lumefantrine (AL), unless contraindicated, as recommended
by the U.S. CDC to prevent symptomatic Plasmodium falci-
parum malaria disease during travel or following arrival.
Treatment is administered in a standard 3-day course under
direct observation and should be completed no sooner than
5 days before departure.
In 2015, in response to the observed high prevalence of
splenomegaly in U.S.-bound Congolese refugees, the CDC
added diagnosis andmanagement recommendations, stating
that all refugees with clinical splenomegaly (enlargement of
the spleen) identified at their initial medical examination (oc-
curring 3–6 months before departure to the United States)
should receive amalaria rapid diagnostic test (RDT; SDBioline
Malaria Ag P.f/Pan test, Abbott Diagnostics Korea Inc.,
Gyeonggido, Republic of Korea) and, if positive, receive
antimalarial treatment with AL. In addition, the CDC re-
commended that all refugees with splenomegaly receive
primaquine after arrival in the United States, if glucose-6-
phosphate dehydrogenase activity is normal, to presump-
tively eliminate Plasmodium vivax and Plasmodium ovale
hypnozoites.
Despite these recommendations, many refugees had per-
sistent splenomegaly months to years after arrival in the
United States.2 In addition, there were increasing reports
of breakthrough malaria, particularly Plasmodium malariae
despite predeparture treatment with AL,2 which was of con-
cern because of increasing reports of AL treatment failure
for P. malariae infections.3 Because P. malariae has been well
associated with splenomegaly,4–6 the reports of P. malariae
in Congolese refugees raised additional concern that the
documented persistent splenomegaly could be related to
inadequate malaria presumptive treatment, especially if
baseline prevalence of P. malariae infection was higher than
expected.
In response to these concerns, and given the continuing high
burden of malaria in U.S.-bound Congolese refugees from
Uganda, the CDC expanded its guidance for malaria testing
and treatment in 2018 to include the RDT for P. falciparum for
all Congolese refugees (with or without splenomegaly) plus
PCR. Refugees with a positive RDT and those diagnosed with
splenomegaly (with or without a positive RDT) were treated with
AL at the initial examination (approximately 6 months before
departure).7 In addition,whenPCR results becameavailable (at a
later date), refugees with positive results who had not previously
receivedappropriate treatment basedonspecies, or hadanewly
identified infection, were offered treatment.8 It should be noted
that in addition to enhanced diagnostics and treatment at initial
medical evaluation, all refugees without a contraindication (in-
cluding those who received previous treatment based on a
positive RDT, positive PCR, or diagnosis of splenomegaly) re-
ceived AL treatment completed no sooner than 5 days before
departure for the United States, consistent with previous guid-
ance.9 An outline of this guidance is provided in Table 1.
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The program was instituted to enhance the diagnosis and
management of malaria in U.S.-bound Congolese refugees.
The goal of this evaluation is to retrospectively report preva-
lence of malaria based on enhanced testing and to correlate
the malaria findings with detection of splenomegaly. The
proposed evaluation was reviewed by a CDC human subject
advisor and determined to be a non-research evaluation of
program activities.
Malaria RDT results were interpreted by International Orga-
nization for Migration laboratory personnel. DNAwas extracted
from blood dried on Whatman 3-MM filter paper with Chelex
(Cetiva, Marlborough, MA),7 with nested PCR amplification of
species-specific sequences of 18S subunit ribosomal RNA
genes and discrimination of species by electrophoresis of
amplicons, as described previously.8 Clinical data, including
the presence of splenomegaly and RDT results, were collected
retrospectively from medical records.
During February–March 2018, 803 refugees had a physical
examination including an abdominal examination and tested
for malaria parasites by RDT and PCR. Demographic char-
acteristics were compared between individuals with and
without detectablemalaria infections using chi-squared tests.
Adjusted odds ratios and 95% CIs were calculated using
multivariable logistic regression models. All models were ad-
justed for age, gender, family size, and birth country.
This cohort consisted of an approximately equal number of
women (51%) and men (49%), with age largely less than 55 (me-
dian = 14, interquartile range = 6–28) years; 41% were born in
Uganda to Congolese parents, and 59%were born in the Demo-
cratic Republic of the Congo (DRC). A total of 187 (23%) refugees
were positive by either RDT or PCR, 78 (10%) were positive by
malaria RDT only, 35 (4%) were positive bymalaria PCR only, and
74 (9%) were positive by both RDT and PCR. In the 109 infections
identifiedbyPCR,87 (80%)hadmonoinfectionswithP. falciparum,
eight (7.3%) with P. ovale, seven (6.4%) with P. vivax, one (0.9%)
with P. malariae, and six (5.5%) mixed infections (Table 2).
Most (75%) malaria infections detected by PCR were among
children aged 14 years and younger. The highest prevalence of
infection was in those aged 6–14 years (24%) and the lowest in
those aged 25–54 years (5%). In the adjusted regression analysis
(Table 3), odds of malaria infection detected by PCR were more
than four timeshigher amongchildrenaged6–14years thanadults
aged25–54years (OR=4.6, 95%CI=1.3–15.6) andalmost seven
times higher among adults aged 55 years or older than that in the
same reference group (OR = 6.6, 95%CI = 2.1–20.5).
TABLE 1
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RDT = rapid diagnostic test.
TABLE 2
Demographic characteristics and screening results of U.S.-bound
Congolese refugees screened for malaria and splenomegaly,
Uganda, 2018





























P. falciparum 87 (80%)
P. malariae 1 (1%)
P. ovale 8 (7%)
P. vivax 7 (6%)
P. falciparum and P. malariae 1 (1%)
P. falciparum and P. ovale 3 (3%)
P. falciparum and P. vivax 1 (1%)




DRC = Democratic Republic of the Congo; P. falciparum = Plasmodium falciparum; P.
malariae = Plasmodium malariae; P. ovale = Plasmodium ovale; P. vivax = Plasmodium vivax.
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Splenomegaly was observed in 92 refugees (11%), with the
highest prevalence among those aged 6–14 years (19%),
similar to previous reports in this population.1 Of the 92 refu-
gees with splenomegaly, malaria parasite infections were
detected by RDT in 27 (29%) and by PCR in 18 (20%).
Adjusting for age, gender, family size, and birth country, odds
of splenomegaly were higher among those with malaria in-
fection detected by PCR than those without (OR = 1.5, 95%
CI = 0.8–2.8) and among those who were RDT positive as
compared with those RDT negative (OR = 1.8, 95% CI =
1.0–3.0), but the association was significant only for the RDT
comparison (Table 3). Of note, among those positive by RDT,
an unusually high proportion (51%) were negative by PCR.
This analysis has limitations. This was a retrospective
analysis of data collected during routine care and not
designed as a prospective study.Malaria prevalencemay vary
as transmission intensity changes over time, and this cross-
sectional investigation offers only a snapshot of the evaluation
period. Furthermore, the high rate of PCR negativity among
those who tested positive by RDT was unexpected because
PCR offers a more sensitive test for parasitemia. Expert mi-
croscopy was not included in the enhanced program evalua-
tion. In the operational setting, either RDT or PCR may have
been inaccurate because of undetermined factors. Potential
contributors to discrepancies between RDT and PCR results
include persistence of circulating histidine-rich protein be-
yond that of plasmodial DNA in those recently treated for
malaria (including self-treatment in advance of their medical
examination for resettlement), errors in reading of RDTs in the
field setting, false-negative PCR assays due to polymerase
inhibitors in samples, and false-positive PCR assays due to
contamination from other samples.9,10
In conclusion, malaria was prevalent in U.S.-bound Con-
golese refugees living in Kikuube district, Uganda, in
February–March 2018. Splenomegaly was prevalent in this
population at rates similar to those found in 2014.1 Efforts to
delineate the optimal treatment regimen for malaria in the
population before migration to the United States would be
beneficial, particularly as 18% of PCR-positive samples had
P. ovale or P. vivax. Traditionally, presumptive treatment has
not focused on relapsing (P. vivax and P. ovale) forms of
malaria because U.S.-bound refugees have mostly not origi-
nated in areas with high prevalence of these parasites. In light
of the prevalence of P. ovale and P. vivax that is higher than
that expected in Congolese refugees, presumptive treatment
for relapsing malaria in some refugee populations should be
reconsidered. There was no clear direct association between
malaria parasitemia and splenomegaly, indicating that active
malaria parasitemia is not necessary for splenomegaly or that
splenomegaly persists over time despite parasite clearance.
Nonetheless, the background high prevalence of malaria in-
fection suggests a likely role for malaria infection in the etiol-
ogy of splenomegaly, as previously suggested.11,12 Despite
anecdotal reports of high prevalence ofP.malariae infection in
Congolese refugees, < 1% of detected species were
P. malariae in this program. The small number of P. malariae
cases identified suggests this species is not a driver of
splenomegaly. Etiologies other thanmalaria that could account
for or contribute to splenomegaly should be further explored.
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Unadjusted odds ratio Adjusted odds ratio* Unadjusted odds ratio Adjusted odds ratio†
95% CI P-value 95% CI P-value 95% CI P-value 95% CI P-value
Age (years)
0–2 – – – – 2.27 (0.90–5.74) 0.078 1.81 (0.44–7.21) 0.398
3–5 0.30 (0.09–1.03) 0.056 0.17 (0.04–0.75) 0.02 4.52 (2.03–10.61) < 0.001 3.45 (0.93–12.81) 0.065
6–14 2.18 (1.23–3.84) 0.007 1.16 (0.42–3.23) 0.774 5.96 (3.07–12.76) < 0.001 4.57 (1.33–15.63) 0.016
15–24 1.54 (0.81–2.95) 0.188 1.00 (0.44–2.28) 0.994 1.35 (0.54–3.39) 0.51 1.36 (0.46–4.05) 0.579
25–54 Ref – Ref – Ref – Ref –
55+ 0.82 (0.23–2.93) 0.763 0.56 (0.15–2.10) 0.389 4.61 (1.57–12.99) 0.004 6.58 (2.11–20.54) 0.001
Gender
Male Ref – Ref – Ref – Ref –
Female 0.75 (0.48–1.15) 0.187 0.74 (0.47–1.17) 0.195 0.86 (0.57–1.28) 0.86 (0.56–1.30) 0.463
Malaria by RDT
Yes 1.95 (1.19–3.17) 0.008 1.75 (1.00–3.04) 0.049 – – – –
No Ref – Ref – – – – –
Malaria by PCR
Yes 1.66 (0.95–2.90) 0.077 1.52 (0.83–2.78) 0.175 – – – –
No Ref – Ref – – – – –
Malaria by PCR or RDT
Yes 2.02 (1.27–3.21) 0.003 1.84 (1.09–3.09) 0.021 – – – –
No Ref – Ref – – – – –
Malaria by PCR and RDT
Yes 1.57 (0.81–3.04) 0.181 1.41 (0.69–2.88) 0.348 – – – –
No Ref – Ref – – – – –
RDT = rapid diagnostic test.
* Four separate models were run for malaria infection detectable by RDT, by PCR, by PCR or RDT, and by PCR and RDT, each adjusted for age, gender, family size, and birth country.
†Model adjusted for age, gender, family size, and birth country.
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